- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT04484909
NBTXR3 aktivovaný radiační terapií pro léčbu lokálně pokročilého nebo hraničně resekovatelného karcinomu pankreatu
Studie fáze I NBTXR3 aktivovaného radioterapií u lokálně pokročilého nebo hraničně resekovatelného duktálního adenokarcinomu pankreatu
To find the recommended dose of NBTXR3 that can be given in combination with radiation therapy to patients with pancreatic cancer. To learn if the dose NBTXR3 found in Part 1 can help to control the disease.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Detailní popis
PRIMARY OBJECTIVE:
• To determine the recommended phase II dose (RP2D) of NBTXR3 activated by radiotherapy in subjects with locally advanced or borderline-resectable pancreatic ductal adenocarcinoma.
SECONDARY OBJECTIVES:
- To evaluate the safety and feasibility of NBTXR3 intratumoral injection activated by radiotherapy in locally advanced or borderline-resectable pancreatic ductal adenocarcinoma
- To evaluate the anti-tumor response of NBTXR3 intratumoral injection activated by radiotherapy in subjects with locally advanced or borderline-resectable pancreatic ductal adenocarcinoma
- To evaluate time-to-event outcomes in subjects with locally advanced or borderline-resectable pancreatic ductal adenocarcinoma
EXPLORATORY OBJECTIVES:
- To evaluate the body kinetic profile of intratumorally injected NBTXR3.
- To evaluate time to event outcomes for subjects with clinical staging of locally advanced, unresectable disease.
- To evaluate resectability conversion rates.
- To evaluate surgical outcomes in subjects who undergo surgery after radiation therapy.
- To associate radiomic measurements with outcomes.
- To evaluate biomarkers of response in subjects treated with NBTXR3/RT.
OUTLINE: This is a dose-escalation study of NBTXR3.
Patients receive NBTXR3 intratumorally (IT) on day 1. Patients then undergo 15 fractions of intensity modulated radiation therapy (IMRT) between days 15-43 in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up at 1 month and then every 3 months for up to 1 year.
Typ studie
Zápis (Odhadovaný)
Fáze
- Fáze 1
Kontakty a umístění
Studijní místa
-
-
Texas
-
Houston, Texas, Spojené státy, 77030
- M D Anderson Cancer Center
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
1. Signed informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study 2. Age ≥ 18 years 3. Biopsy proven ductal adenocarcinoma of the pancreas,as defined by the following:
a. Borderline resectable pancreatic adenocarcinoma (BRPC) has no aortic involvement with at least ONE of the following features: i. Superior mesenteric vein (SMV) or Portal vein (PV) with a tumor interface of ≥ 180° OR short segment occlusion of SMV or PV amenable to reconstruction ii. Superior mesenteric artery (SMA) or celiac axis (CA) with a tumor interface of < 180° iii. Any degree of hepatic artery interface that is amenable to reconstruction b. Locally advanced pancreatic adenocarcinoma (LAPC) has at least ONE of the following features:
-
Signed informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study
-
Age ≥ 18 years
-
Biopsy proven ductal adenocarcinoma of the pancreas,as defined by the following:
a. Borderline resectable pancreatic adenocarcinoma (BRPC) has no aortic involvement with at least ONE of the following features: i. Superior mesenteric vein (SMV) or Portal vein (PV) with a tumor interface of ≥ 180° OR short segment occlusion of SMV or PV amenable to reconstruction ii. Superior mesenteric artery (SMA) or celiac axis (CA) with a tumor interface of < 180° iii. Any degree of hepatic artery interface that is amenable to reconstruction b. Locally advanced pancreatic adenocarcinoma (LAPC) has at least ONE of the following features: i. Occlusion of the SMV or PV that is not amenable to reconstruction ii. Tumor interface of the superior mesenteric artery or celiac axis ≥ 180° iii. Involvement of the hepatic artery that is not amenable to reconstruction iv. Involvement of the aorta
-
Has had a 4-month course (± 2-months) of chemotherapy for PDAC without radiographic evidence of distant metastatic disease. Following chemotherapy regimens are allowed:
- gemcitabine/nab-paclitaxel
- gemcitabine/capecitabine
- gemcitabine/cisplatin
- gemcitabine
- FOLFOX
- FOLFIRINOX
-
Amenable to undergo the endoscopic ultrasound guided injection of NBTXR3 as per investigator or treating physician.
-
Has a target lesion in the pancreas that is identifiable on cross sectional imaging by repeated measurements (via RECIST 1.1) at the same anatomical location
a. Nodal disease only is not allowed.
-
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
-
Laboratory Values at screening:
- Hemoglobin ≥ 8.0 g/dL
- Absolute Neutrophil Count (ANC) ≥ 1,500/mm3
- Platelet Count ≥ 100,000/mm3
- Creatinine ≤ 1.5 x upper limit of normal (ULN)
- Total Bilirubin ≤ 2.0 mg/dL
- AST / ALT ≤ 3.0 x upper limit of normal (ULN)
- Serum albumin ≥ 3.0 g/dL
-
Negative pregnancy test ≤ 7 days prior to NBTXR3 injection in all females of child-bearing potential
-
If participant has a history of prior duodenal or biliar plastic stent, it should be replaced with a metal stent ≥ 1 week prior to Study Day 1.
Exclusion Criteria:
-
Prior radiation therapy to the upper abdomen
-
Prior surgical resection of pancreatic tumor
-
Diagnosis other than pancreatic ductal adenocarcinoma. All other histologic types (i.e., adenosquamous, cystadenocarcinoma, etc.) are not eligible to participate on this study.
-
LAPC or BRPC with radiographic evidence of distant metastasis at screening.
-
Has received any approved or investigational anti-neoplastic agent other than the chemotherapies specified in this protocol (i.e. chemotherapies included in Inclusion #4)
-
Known uncontrolled (Grade ≥ 2) or active gastric or duodenal ulcer disease within 30 days of enrollment
-
Known contraindication to iodine-based or gadolinium-based IV contrast
-
Active malignancy, in addition to pancreatic cancer, with the exception of basal cell carcinoma of the skin definitively treated and relapse free within at least 1 year from diagnosis
-
Clinically significant cardiac arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsades de pointes, second or third degree atrioventricular heart block without a permanent pacemaker in place)
-
Class III or IV Congestive Heart Failure as defined by the New York Heart Association functional classification system <6 months prior to screening
-
Known active, uncontrolled (high viral load) HIV or hepatitis B or hepatitis C infection
a. Patients who have been vaccinated for hepatitis B and do not have a history of infection are eligible.
-
Female patients who are pregnant or breastfeeding
-
Women of child-bearing potential and their male partners who are unwilling or unable to use an acceptable method of birth control for the entire study period. Acceptable methods of contraception are those that, alone or in combination, result in a failure rate of < 1% per year when used consistently and correctly
-
Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Experimentální: Treatment (NBTXR3, radiation therapy)
Patients receive NBTXR3 IT on day 1. Patients then undergo 15 fractions of radiation therapy between days 15-43 in the absence of disease progression or unacceptable toxicity. |
Undergo radiation therapy
Ostatní jména:
Given IT
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Doporučená dávka fáze II (RP2D)
Časové okno: Do 1 roku
|
Do 1 roku
|
|
|
Dose-limiting toxicities
Časové okno: 4 weeks after last radiation dose
|
Any grade >= 3 adverse event related to NBTXR3 and/or radiation therapy. Any toxicity (grade >= 3) that is at least possibly related to study drug (NBTXR3) is a DLT. Adverse events will be scored based on National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE v 5.0). |
4 weeks after last radiation dose
|
|
Maximum tolerated dose (MTD)
Časové okno: Up to 1 year
|
MTD will be determined as the dose for which the isotonic estimate of the toxicity rate is closest to the target toxicity rate 30%. |
Up to 1 year
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Přežití bez progrese (PFS)
Časové okno: Od injekce NBTXR3 po lokální recidivu, lokální progresi, vzdálenou progresi nebo úmrtí z jakékoli příčiny, podle toho, co nastane dříve, hodnoceno do 1 roku
|
Od injekce NBTXR3 po lokální recidivu, lokální progresi, vzdálenou progresi nebo úmrtí z jakékoli příčiny, podle toho, co nastane dříve, hodnoceno do 1 roku
|
|
|
Celkové přežití (OS)
Časové okno: Od injekce NBTXR3 po smrt z jakékoli příčiny nebo EoS, podle toho, co nastane dříve, hodnoceno do 1 roku
|
Od injekce NBTXR3 po smrt z jakékoli příčiny nebo EoS, podle toho, co nastane dříve, hodnoceno do 1 roku
|
|
|
Determination of the feasibility of NBTXR3 injection in pancreas
Časové okno: Up to 1 year
|
Feasibility refers to the ability to do intratumoral injection of NBTXR3. The outcome for each patient would be "feasible" or "not feasible." |
Up to 1 year
|
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Podíl lokálně pokročilých subjektů, kteří podstoupili chirurgickou resekci po podání NBTXR3/radiační terapie (R3/RT)
Časové okno: Do 1 roku
|
Do 1 roku
|
|
|
Presence of hafnium
Časové okno: Up to 1 year
|
Will evaluation of the time-course dependent presence of hafnium in blood and urine following NBTXR3 intratumoral injection. |
Up to 1 year
|
|
Disease control rate
Časové okno: 6 months
|
Defined as the proportion of patients without progression 6 months post NBTXR3 injection. |
6 months
|
|
Resection status
Časové okno: Up to 1 year
|
Resection status as assessed macroscopically by surgeon R0- Macroscopically complete tumor removal with negative microscopic surgical margins, R1- Macroscopically complete tumor removal with positive microscopic margins (any or all), and R2- Macroscopically incomplete tumor removal with known or suspected residual gross disease. |
Up to 1 year
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Vrchní vyšetřovatel: Eugene J Koay, M.D. Anderson Cancer Center
Publikace a užitečné odkazy
Užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Odhadovaný)
Dokončení studie (Odhadovaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- 2019-1001
- 2019-1001 (Jiný identifikátor: M D Anderson Cancer Center)
- NCI-2020-03731 (Identifikátor registru: CTRP (Clinical Trial Reporting Program))
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .